Preliminary results on clinical and endocrine studies in the treatment of menorrhagia with danazol.

Preliminary results are presented on the effect of 400, 200 and 100 mg of daily danazol on measured menstrual blood loss, in women with menorrhagia. Both 400 and 200 mg daily effectively suppressed menstrual blood loss, 400 mg reducing menstrual blood loss from a pretreatment mean of 456 +/- 48 ml to 45 +/- 26 ml and 6 +/- 5 ml during the second and third months of treatment. Menstrual blood loss on 100 mg danazol was only minimally reduced. After two to three months on danazol, the pituitary showed ability to respond to gonadotrophin releasing hormone and to oestradiol benzoate. A lack of effect of danazol on most coagulation and fibrinolytic factors was demonstrated.
AuthorsT H Chimbira, A B Anderson, E Cope, A C Turnbull
JournalPostgraduate medical journal (Postgrad Med J) Vol. 55 Suppl 5 Pg. 90-4 ( 1979) ISSN: 0032-5473 [Print] ENGLAND
PMID395527 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Pregnadienes
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Danazol
  • Blood Coagulation Tests
  • Clinical Trials as Topic
  • Danazol (administration & dosage, therapeutic use)
  • Drug Administration Schedule
  • Female
  • Follicle Stimulating Hormone (blood)
  • Humans
  • Luteinizing Hormone (blood)
  • Menorrhagia (blood, drug therapy)
  • Pregnadienes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: